Protagonist Therapeutics Current Ratio 2015-2021 | PTGX

Protagonist Therapeutics current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Protagonist Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-09-30 $0.33B $0.04B 8.37
2021-06-30 $0.37B $0.04B 8.65
2021-03-31 $0.29B $0.04B 8.27
2020-12-31 $0.32B $0.04B 7.84
2020-09-30 $0.20B $0.04B 5.29
2020-06-30 $0.22B $0.04B 6.15
2020-03-31 $0.13B $0.04B 3.46
2019-12-31 $0.15B $0.04B 4.10
2019-09-30 $0.14B $0.03B 4.68
2019-06-30 $0.14B $0.03B 4.12
2019-03-31 $0.12B $0.02B 5.02
2018-12-31 $0.14B $0.03B 5.26
2018-09-30 $0.15B $0.02B 6.12
2018-06-30 $0.14B $0.03B 4.69
2018-03-31 $0.14B $0.03B 4.19
2017-12-31 $0.15B $0.04B 3.55
2017-09-30 $0.10B $0.05B 1.87
2017-06-30 $0.07B $0.01B 7.38
2017-03-31 $0.07B $0.01B 8.68
2016-12-31 $0.08B $0.01B 12.94
2016-09-30 $0.10B $0.01B 19.12
2016-06-30 $0.02B $0.00B 5.45
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2014-12-31 $0.01B $0.00B 7.34
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.518B $0.029B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00